PTGS1 and type 2 diabetes mellitus: ASP is well known for its anti-inflammatory potential resulting from the inhibition of cyclooxygenase-1 (COX-1) and COX-2 [6], whereas MET is used as the first-line treatment for type 2 diabetes mellitus (T2DM) [7].